Human vascular cells from saphenous veins have been used for cell seeding on the synthetic scaffolds for constructing tissue-engineered heart valve (TEHV). However, little is known about the seeding of human vascular cells on bovine pericardium, a potential natural scaffold for TEHV. This study was aimed to assess the basic in vitro and in vivo characteristics of the human vascular cells seeded on decellularized bovine pericardium. In vitro, bovine pericardium samples with cell seeding were inspected on day 7, 14, and 21 by histology, scanning electron microscopy, and immunohistochemistry. In vivo, experiments were performed in nude mice by bilateral dorsal incision for the implantation of decellularized bovine pericardium with and without cell seeding. Results demonstrated that a total of 8-10 × 10(6) cells were obtained within 4-5 wk by the primary co-culture, which were detected positive for von Willebrand factor, α-smooth muscle actin antibodies, and fibronectin, indicating the presence of endothelial cells, smooth muscle cells, and fibroblasts, respectively. In vitro, the seeded cells showed a steady increase of endothelial activity from day 1 to day 7 and remained stable until day 21. After 30 days of implantation in vivo, the cells on the decellularized bovine pericardium could differentiate directionally and show all the identities of human endothelial cells, smooth muscle cells, and fibroblasts. These results indicate that the human vascular cells from the saphenous vein are an optional cell source for seeding on decellularized bovine pericardium scaffold for constructing TEHV.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/jbm.b.32734 | DOI Listing |
Histol Histopathol
December 2024
Department of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy.
Research towards regenerative dentistry focused on developing scaffold materials whose high performance induces cell adhesion support and guides tissue growth. An early study investigated the proliferation abilities and attachment of human periodontal ligament fibroblasts (HPLFs) on two bovine pericardium membranes with different thicknesses, 0.2 mm and 0.
View Article and Find Full Text PDFCureus
November 2024
Cardiovascular Surgery, Nihon University School of Medicine, Tokyo, JPN.
Double-chambered right ventricle (DCRV) is a congenital heart disease. Most cases of DCRV are complicated by another congenital cardiac anomaly. Mostly, a ventricular septal defect (VSD) is the usual comorbidity.
View Article and Find Full Text PDFInt Braz J Urol
December 2024
Serviço de Urologia - Hospital Federal da Lagoa, Rio de Janeiro, RJ, Brasil.
Objective: The current management for complex urethral strictures commonly uses open reconstruction with buccal mucosa urethroplasty. However, there are multiple situations whereby buccal mucosa is inadequate (pan-urethral stricture or prior buccal harvest) or inappropriate for utilization (heavy tobacco use or oral radiation). Multiple options exist for use as alternatives or adjuncts to buccal mucosa in complex urethral strictures (injectable antifibrotic agents, augmentation urethroplasty with skin flaps, lingual mucosa, bladder mucosa, colonic mucosa, and new developments in tissue engineering for urethral graft material) (1, 2).
View Article and Find Full Text PDFPolymers (Basel)
November 2024
Icon Lab Gmbh Ltd., 1 Barrikad St., Nizhny Novgorod 603003, Russia.
Polymer heart valves are a promising alternative to bioprostheses, the use of which is limited by the risks of calcific deterioration of devitalized preserved animal tissues. This is especially relevant in connection with the increasingly widespread use of transcatheter valves. Advances in modern organic chemistry provide a wide range of polymers that can replace biological material in the production of valve prostheses.
View Article and Find Full Text PDFIndian J Thorac Cardiovasc Surg
January 2025
Army Hospital R&R, Delhi, India.
Aim: To evaluate the short-term outcomes of Tissue Engineered Decellularized Bovine pericardium (Synkroscaff®) in congenital heart surgery as a prosthetic material.
Methodology: This is a prospective observational cohort study. SynkroScaff® was used as prosthetic material in cohort of successive patients under 18 years of age requiring cardiac surgery for congenital heart diseases.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!